FGF-21 agonists such as efruxifermin and pegozafermin have also shown promising results in reducing liver fat and improving NASH markers, with pegozafermin at 27 mg achieving a notable ΔΔLFC of 14.87%. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.